Caribou Biosciences’ (CRBU) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Caribou Biosciences (NASDAQ:CRBU) in a report released on Friday morning,Benzinga reports. The brokerage currently has a $9.00 price objective on the stock.

Separately, Royal Bank of Canada reiterated an “outperform” rating and set a $14.00 target price on shares of Caribou Biosciences in a research note on Wednesday, August 7th.

Caribou Biosciences Trading Down 0.5 %

NASDAQ:CRBU opened at $1.98 on Friday. The stock has a fifty day moving average price of $2.05 and a 200 day moving average price of $2.21. Caribou Biosciences has a 12-month low of $1.50 and a 12-month high of $8.33. The firm has a market cap of $179.29 million, a PE ratio of -1.20 and a beta of 2.26.

Caribou Biosciences (NASDAQ:CRBU) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.38) EPS for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.06. The business had revenue of $2.02 million during the quarter, compared to the consensus estimate of $3.37 million. Caribou Biosciences had a negative return on equity of 45.46% and a negative net margin of 1,290.81%. Equities analysts forecast that Caribou Biosciences will post -1.67 EPS for the current year.

Institutional Trading of Caribou Biosciences

Several institutional investors have recently modified their holdings of the stock. Erste Asset Management GmbH purchased a new position in shares of Caribou Biosciences in the 3rd quarter valued at $28,000. China Universal Asset Management Co. Ltd. increased its position in shares of Caribou Biosciences by 63.8% during the third quarter. China Universal Asset Management Co. Ltd. now owns 17,380 shares of the company’s stock worth $34,000 after purchasing an additional 6,768 shares in the last quarter. AQR Capital Management LLC purchased a new stake in shares of Caribou Biosciences in the 2nd quarter valued at about $30,000. Entropy Technologies LP acquired a new stake in shares of Caribou Biosciences in the 1st quarter valued at about $113,000. Finally, Intech Investment Management LLC purchased a new position in Caribou Biosciences during the 3rd quarter worth approximately $43,000. Hedge funds and other institutional investors own 77.51% of the company’s stock.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.